Study explores opportunity to shift from clinic to home instillation of this promising non-surgical treatment
Potential to transform care and access to treatment for this growing patient population
San Francisco, CA (UroToday.com) — UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, announced that the first patient has received their first dose in its home instillation study of UGN-102 in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).